Advanced search
Publication Cover
Clinical Toxicology Volume 55, 2017 - Issue 1
Submit an article Journal homepage
270
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Letter in response to “Idarucizumab for dabigatran overdose”

Josh J. WangEmergency Medicine Residency program, McGill University, Montreal, CanadaCorrespondence[email protected]
,
Eric VilleneuveDepartment of Pharmacy, McGill University Health Centre, Montreal, Canada
&
Sophie GosselinCentre Antipoison du Quebec, Quebec, Canada;Departments of Medicine and Emergency Medicine, McGill University Health Centre, Montreal, Canada
Page 65 | Received 30 Jul 2016, Accepted 13 Sep 2016, Published online: 06 Oct 2016

References

  • Peetermans M, Pollack C Jr, Reilly P, et al. Idarucizumab for dabigatran overdose. Clin Toxicol. 2016. [Epub head of print]. doi: http://dx.doi.org/10.1080/15563650.2016.1187737.
  • Bouchard J, Ghannoum M, Bernier-Jean A, et al. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. Clin Toxicol. 2015;53:156–163.
  • Vlad I, Armstrong J, Ridgley J, et al. Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring. Clin Toxicol. 2016. [Epub ahead of print]. doi: http://dx.doi.org/10.3109/15563650.2015.1126287.
  • Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol. 2014;63:321–328.
  • Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
  • Stöllberger C, Pommer P, Schneider B, et al. Concerns about idarucizumab for dabigatran reversal. Blood Coagul Fibrinolysis. 2016;27:473–474.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.